PRO-169
Asset
- Stage
- Phase 3
- Modality
- Antibody
- Target
- Not known
- 1
- Indication
- 2,013
- Trials
- 1
- Developer
Trial NCT05217680 completed on Nov 25, 2025. clinicaltrials.gov
Indications
1Diabetic macular edema
Phase 3, Completed, NCT05217680, clinicaltrials.gov, Oct 30, 2026
In the full profile
- Target and mechanism1
- Owner and partners1
- Trials2,013
- Evidence for its targets1
- Competitors12
- Signals13
Every asset’s record: target, stage, trials and the evidence behind it.